Sells patient-specific immune-cell therapies for solid tumors and an interleukin medicine to hospitals, clinics and distributors.
10-K for FY2025, filed Feb 24, 2026We are a commercial-stage biopharmaceutical company pioneering a transformational approach to treating cancer. Our mission is to be the…View ↗
Our two commercial products include Amtagvi® (lifileucel) and Proleukin® (aldesleukin), an interleukin-2, or IL-2, product used in the…View ↗
Amtagvi® is the first one-time, individualized T cell therapy for a solid tumor cancer and for the treatment of adult patients with…View ↗
We sell Proleukin® (aldesleukin), an interleukin-2, or IL-2, product to three main distributors in the U.S., distributors outside the U.S.…View ↗
Customers buy Amtagvi for treatment, with sales tied to patient infusion; Proleukin sales are tied to shipment or delivery.
10-K for FY2025, filed Feb 24, 2026
10-K for FY2025, filed Feb 24, 2026
FY2025 revenue by product or service ↗$263.5M
10-K for FY2025, filed Feb 24, 2026
$263.5M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Amtagvi
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
84% |
Amtagvi, FY2025
$220M Sources
|
Sold outright |
|
PROLEUKIN
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
17% |
PROLEUKIN, FY2025
$43.5M Sources
|
Sold outright |
Hospitals and clinics buy products, alongside U.S. distributors and wholesalers; Proleukin also goes through distributors abroad and to clinical, manufacturing and research customers.
10-K for FY2025, filed Feb 24, 2026We sell Proleukin® (aldesleukin), an interleukin-2, or IL-2, product to three main distributors in the U.S., distributors outside the U.S.…View ↗
In the U.S., products are sold principally to hospitals and clinics, as well as distributors and wholesalers, and outside of the U.S. to…View ↗
Revenue from Proleukin® was primarily related to sales made to specialty distributors and authorized treatment centers (“ATCs”) in the U.S.…View ↗
No. It lost $391M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$22.3MView ↗
8-K, filed Jun 10, 2026
On June 4, 2026, the Company received marketing authorization from the Therapeutic Goods Administration of Australia for Amtagvi® for…View ↗
From development to commercial sales
The business moved from preparing to commercialize lifileucel to selling Amtagvi as an approved treatment, and added Proleukin after acquiring worldwide rights.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 24, 2026We are a clinical-stage biopharmaceutical company pioneering a transformational approach to treating cancer by harnessing the human immune…View ↗
We are a commercial-stage biopharmaceutical company pioneering a transformational approach to treating cancer. Our mission is to be the…View ↗
Our two commercial products include Amtagvi® (lifileucel) and Proleukin® (aldesleukin), an interleukin-2, or IL-2, product used in the…View ↗
Amtagvi® is the first one-time, individualized T cell therapy for a solid tumor cancer and for the treatment of adult patients with…View ↗
In May 2023, we acquired the worldwide rights to Proleukin® from Clinigen Holdings Limited, Clinigen Healthcare Limited, and Clinigen…View ↗
Loading...